Dr. Stadtmauer on BCMA-Targeting in Multiple Myeloma

Video

Edward A. Stadtmauer, MD, discusses what makes BCMA a unique target in multiple myeloma.

Edward A. Stadtmauer, MD, section chief, Hematologic Malignancies, and Roseman, Tart, Harrow, and Shaffer Families’ President’s Distinguished Professor, University of Pennsylvania, discusses what makes BCMA a unique target in multiple myeloma.

Similar to CD19-targeting in lymphoma, BCMA-targeting prevents on-target, off-tumor toxicity, explains Stadtmauer. Most tissue in the body does not express BCMA, continues Stadtmauer. However, mature lymphoid cells such as plasma cells do, which creates an actionable target.

As such, success in targeting BCMA in multiple myeloma has been noted through CAR T-cell therapy and other immunotherapeutic agents that arecurrently in development.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD